Loading...
Loading...
Enanta Pharmaceuticals
ENTA today announced that
additional data from AbbVie's M13-393
ABBV study, referred to as PEARL-I,
will be presented in an oral presentation at 5:15 p.m. ET today at The
Liver Meeting, the 64th Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD) in Washington, D.C.
In PEARL-I, SVR12 rates of 95% (40/42) in hepatitis C (HCV) GT-1b
treatment-naïve patients and 90% (36/40) among prior null responders
will be presented in this intent-to-treat analysis. Two patients in the
treatment-naive arm did not achieve SVR12 due to loss to follow up. In
the
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in